Literature DB >> 28188128

Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Hannah Carter1,2,3,4, Rachel Marty5, Matan Hofree6, Andrew M Gross5, James Jensen5, Kathleen M Fisch7,2,3,8, Xingyu Wu2, Christopher DeBoever5, Eric L Van Nostrand4,9, Yan Song4,9, Emily Wheeler4,9, Jason F Kreisberg7,3, Scott M Lippman2, Gene W Yeo4,9, J Silvio Gutkind2,3, Trey Ideker7,2,3,4,5,6.   

Abstract

Recent studies have characterized the extensive somatic alterations that arise during cancer. However, the somatic evolution of a tumor may be significantly affected by inherited polymorphisms carried in the germline. Here, we analyze genomic data for 5,954 tumors to reveal and systematically validate 412 genetic interactions between germline polymorphisms and major somatic events, including tumor formation in specific tissues and alteration of specific cancer genes. Among germline-somatic interactions, we found germline variants in RBFOX1 that increased incidence of SF3B1 somatic mutation by 8-fold via functional alterations in RNA splicing. Similarly, 19p13.3 variants were associated with a 4-fold increased likelihood of somatic mutations in PTEN. In support of this association, we found that PTEN knockdown sensitizes the MTOR pathway to high expression of the 19p13.3 gene GNA11 Finally, we observed that stratifying patients by germline polymorphisms exposed distinct somatic mutation landscapes, implicating new cancer genes. This study creates a validated resource of inherited variants that govern where and how cancer develops, opening avenues for prevention research.Significance: This study systematically identifies germline variants that directly affect tumor evolution, either by dramatically increasing alteration frequency of specific cancer genes or by influencing the site where a tumor develops. Cancer Discovery; 7(4); 410-23. ©2017 AACR.See related commentary by Geeleher and Huang, p. 354This article is highlighted in the In This Issue feature, p. 339. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28188128      PMCID: PMC5460679          DOI: 10.1158/2159-8290.CD-16-1045

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  76 in total

1.  A comparative investigation of methods for logistic regression with separated or nearly separated data.

Authors:  Georg Heinze
Journal:  Stat Med       Date:  2006-12-30       Impact factor: 2.373

2.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap.

Authors:  Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker
Journal:  Bioinformatics       Date:  2008-10-30       Impact factor: 6.937

3.  Epigenetic down-regulated DDX10 promotes cell proliferation through Akt/NF-κB pathway in ovarian cancer.

Authors:  Muhuizi Gai; Qifang Bo; Lixia Qi
Journal:  Biochem Biophys Res Commun       Date:  2015-12-20       Impact factor: 3.575

4.  Next-generation genotype imputation service and methods.

Authors:  Sayantan Das; Lukas Forer; Sebastian Schönherr; Carlo Sidore; Adam E Locke; Alan Kwong; Scott I Vrieze; Emily Y Chew; Shawn Levy; Matt McGue; David Schlessinger; Dwight Stambolian; Po-Ru Loh; William G Iacono; Anand Swaroop; Laura J Scott; Francesco Cucca; Florian Kronenberg; Michael Boehnke; Gonçalo R Abecasis; Christian Fuchsberger
Journal:  Nat Genet       Date:  2016-08-29       Impact factor: 38.330

Review 5.  Highly penetrant hereditary cancer syndromes.

Authors:  Rebecca Nagy; Kevin Sweet; Charis Eng
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

6.  Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia.

Authors:  Catherine Tcheandjieu; Fabienne Lesueur; Marie Sanchez; Dominique Baron-Dubourdieu; Anne-Valerie Guizard; Claire Mulot; Pierre Laurent-Puig; Claire Schvartz; Therese Truong; Pascal Guenel
Journal:  Int J Cancer       Date:  2016-03-30       Impact factor: 7.396

Review 7.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 8.  GNAQ and GNA11 mutations in uveal melanoma.

Authors:  Alexander N Shoushtari; Richard D Carvajal
Journal:  Melanoma Res       Date:  2014-12       Impact factor: 3.599

9.  Integrated analysis of germline and somatic variants in ovarian cancer.

Authors:  Krishna L Kanchi; Kimberly J Johnson; Charles Lu; Michael D McLellan; Mark D M Leiserson; Michael C Wendl; Qunyuan Zhang; Daniel C Koboldt; Mingchao Xie; Cyriac Kandoth; Joshua F McMichael; Matthew A Wyczalkowski; David E Larson; Heather K Schmidt; Christopher A Miller; Robert S Fulton; Paul T Spellman; Elaine R Mardis; Todd E Druley; Timothy A Graubert; Paul J Goodfellow; Benjamin J Raphael; Richard K Wilson; Li Ding
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  Functional impact bias reveals cancer drivers.

Authors:  Abel Gonzalez-Perez; Nuria Lopez-Bigas
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

View more
  55 in total

1.  Common genetic variation in the germline influences where and how tumors develop.

Authors:  Hannah Carter; Trey Ideker
Journal:  Mol Cell Oncol       Date:  2017-03-10

2.  Genomics: A different view of the landscape.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2017-03-10       Impact factor: 60.716

Review 3.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

Review 4.  Germline Variants Impact Somatic Events during Tumorigenesis.

Authors:  Johnny R Ramroop; Madelyn M Gerber; Amanda Ewart Toland
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

5.  A protein-centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes.

Authors:  Ginny X H Li; Dan Munro; Damian Fermin; Christine Vogel; Hyungwon Choi
Journal:  Hum Mutat       Date:  2020-01-23       Impact factor: 4.878

6.  The Germline Variants rs61757955 and rs34988193 Are Predictive of Survival in Lower Grade Glioma Patients.

Authors:  Ajay Chatrath; Manjari Kiran; Pankaj Kumar; Aakrosh Ratan; Anindya Dutta
Journal:  Mol Cancer Res       Date:  2019-01-16       Impact factor: 5.852

7.  Exploring the Link between the Germline and Somatic Genome in Cancer.

Authors:  Paul Geeleher; R Stephanie Huang
Journal:  Cancer Discov       Date:  2017-04       Impact factor: 39.397

8.  Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture.

Authors:  Derek M van Pel; Kaori Harada; Dandan Song; Christian C Naus; Wun Chey Sin
Journal:  J Cell Commun Signal       Date:  2018-06-16       Impact factor: 5.782

9.  Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.

Authors:  Xiang Shu; Jianchun Gu; Maosheng Huang; Nizar M Tannir; Surena F Matin; Jose A Karam; Christopher G Wood; Xifeng Wu; Yuanqing Ye
Journal:  Carcinogenesis       Date:  2018-05-28       Impact factor: 4.944

10.  Evolutionary Pressure against MHC Class II Binding Cancer Mutations.

Authors:  Rachel Marty Pyke; Wesley Kurt Thompson; Rany M Salem; Joan Font-Burgada; Maurizio Zanetti; Hannah Carter
Journal:  Cell       Date:  2018-09-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.